List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7282823/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Consensus guidelines for diagnosis, prophylaxis and management of <scp><i>P</i></scp> <i>neumocystis jirovecii</i> pneumonia in patients with haematological and solid malignancies, 2014. Internal Medicine Journal, 2014, 44, 1350-1363.	0.8	169
2	Managing haematology and oncology patients during the <scp>COVID</scp> â€19 pandemic: interim consensus guidance. Medical Journal of Australia, 2020, 212, 481-489.	1.7	107
3	Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. British Journal of Haematology, 2015, 171, 100-108.	2.5	94
4	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Frontiers in Immunology, 2020, 11, 579250.	4.8	72
5	Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica, 2015, 100, e28-e31.	3.5	62
6	Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Blood Reviews, 2018, 32, 499-507.	5.7	57
7	Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Advances, 2022, 6, 2014-2034.	5.2	57
8	Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection. Blood Reviews, 2014, 28, 75-86.	5.7	52
9	Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. European Journal of Cancer, 2016, 67, 21-37.	2.8	49
10	Azole antifungals and new targeted therapies for hematological malignancy. Current Opinion in Infectious Diseases, 2019, 32, 538-545.	3.1	49
11	CAR-T cell therapy and infection: a review. Expert Review of Anti-Infective Therapy, 2021, 19, 749-758.	4.4	47
12	Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs. BMJ Open Quality, 2018, 7, e000355.	1.1	41
13	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Internal Medicine Journal, 2021, 51, 67-88.	0.8	36
14	Impact of swine influenza and quarantine measures on patients and households during the H1N1/09 pandemic. Scandinavian Journal of Infectious Diseases, 2012, 44, 289-296.	1.5	34
15	Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica, 2015, 100, e462-e466.	3.5	30
16	Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Supportive Care in Cancer, 2015, 23, 1901-1906.	2.2	30
17	Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing. Biology of Blood and Marrow Transplantation, 2018, 24, 1490-1496.	2.0	29
18	Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia. Clinical Microbiology and Infection, 2012, 18, E71-E73.	6.0	26

#	Article	IF	CITATIONS
19	Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. European Journal of Haematology, 2017, 98, 149-153.	2.2	26
20	Lateâ€onset <i><scp>P</scp>neumocystis jirovecii</i> pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. European Journal of Haematology, 2013, 91, 157-163.	2.2	23
21	Disseminated <i>Scedosporium prolificans</i> infection in an †extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics. Mycoses, 2014, 57, 572-576.	4.0	23
22	Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study. Supportive Care in Cancer, 2017, 25, 1923-1930.	2.2	22
23	Home-based care of low-risk febrile neutropenia in children—an implementation study in a tertiary paediatric hospital. Supportive Care in Cancer, 2021, 29, 1609-1617.	2.2	20
24	Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. Expert Review of Anti-Infective Therapy, 2015, 13, 1325-1336.	4.4	19
25	The epidemiology of <i>Clostridium difficile</i> infection in patients with cancer. Expert Review of Anti-Infective Therapy, 2016, 14, 1077-1085.	4.4	19
26	High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 1572-1575.	1.3	19
27	Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. Supportive Care in Cancer, 2018, 26, 997-1003.	2.2	18
28	Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 444-450.e3.	0.4	17
29	Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting. BMC Infectious Diseases, 2020, 20, 228.	2.9	16
30	Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. Blood Reviews, 2021, 49, 100810.	5.7	15
31	[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Haematology,the, 2022, 9, e573-e584.	4.6	15
32	A different kind of "allogeneic transplant― successful fecal microbiota transplant for recurrent and refractoryClostridium difficileinfection in a patient with relapsed aggressive B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 512-514.	1.3	14
33	Sepsis following cancer surgery: the need for early recognition and standardised clinical care. Expert Review of Anti-Infective Therapy, 2016, 14, 425-433.	4.4	14
34	A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease. Transplant Infectious Disease, 2013, 15, E134-8.	1.7	12
35	<scp>COVID</scp> â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 2021, 51, 763-768.	0.8	12
36	<i>Pneumocystis jirovecii</i> pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. Leukemia and Lymphoma, 2015, 56, 157-162.	1.3	11

#	Article	IF	CITATIONS
37	A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 73, e4269-e4277.	5.8	11
38	Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients. Current Opinion in Infectious Diseases, 2021, 34, 297-306.	3.1	11
39	Molecular diagnosis of Pneumocystis jirovecii in patients with malignancy: Clinical significance of quantitative polymerase chain reaction. Medical Mycology, 2014, 52, 427-432.	0.7	10
40	Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling. Frontiers in Immunology, 2017, 8, 1247.	4.8	10
41	Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Supportive Care in Cancer, 2020, 28, 2745-2752.	2.2	9
42	Impact of a dedicated post-transplant vaccination service at an Australian cancer centre. Bone Marrow Transplantation, 2017, 52, 1681-1683.	2.4	8
43	Costâ€effectiveness of homeâ€based care of febrile neutropenia in children with cancer. Pediatric Blood and Cancer, 2022, 69, e29469.	1.5	8
44	Hepatitis <scp>B</scp> serological changes following allogeneic bone marrow transplantation. Transplant Infectious Disease, 2013, 15, 98-103.	1.7	7
45	Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies. Leukemia and Lymphoma, 2016, 57, 1719-1722.	1.3	7
46	<i>Candida glabrata</i> fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy. Leukemia and Lymphoma, 2015, 56, 3442-3444.	1.3	6
47	Cryptococcal infection in patients with haematological and solid organ malignancy in the era of targeted and immune-based therapies. Clinical Microbiology and Infection, 2020, 26, 519-521.	6.0	6
48	Levofloxacin prophylaxis in patients with myeloma. Lancet Oncology, The, 2020, 21, e67.	10.7	6
49	Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns. Leukemia and Lymphoma, 2020, 61, 2292-2294.	1.3	5
50	Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi entre cohort study. Mycoses, 2021, 64, 30-34.	4.0	5
51	Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy. Leukemia and Lymphoma, 2021, 62, 2820-2822.	1.3	5
52	Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for nonâ€smallâ€cell lung carcinoma. Internal Medicine Journal, 2012, 42, 1269-1270.	0.8	4
53	Correspondence on â€~Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'. Annals of the Rheumatic Diseases, 2021, 80, e33-e33.	0.9	4
54	Miliary Tuberculosis Following Negative Latent Tuberculosis Infection Screening Prior to Tumor Necrosis Factor-α Antagonists: Implications for Management?. Journal of Rheumatology, 2012, 39, 1297-1298.	2.0	3

#	Article	IF	CITATIONS
55	<i>Staphylococcus aureus</i> meningitis: barriers to treatment. Leukemia and Lymphoma, 2012, 53, 1443-1444.	1.3	3
56	Impact of a hospitalâ€wide sepsis pathway on improved quality of care and clinical outcomes in surgical patients at a comprehensive cancer centre. European Journal of Cancer Care, 2019, 28, e13018.	1.5	3
57	Successful identification of predictive profiles for infection utilising systemsâ€level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma. Clinical and Translational Immunology, 2021, 10, e1235.	3.8	3
58	National cost savings from an ambulatory program for low-risk febrile neutropenia patients in Australia. Australian Health Review, 2019, 43, 549-555.	1.1	3
59	Guarding the sleeping giant: hepatitis B screening and management in patients with hematological malignancy. Leukemia and Lymphoma, 2014, 55, 2426-2427.	1.3	2
60	Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature. Leukemia and Lymphoma, 2021, 62, 1271-1274.	1.3	1
61	Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach?. Supportive Care in Cancer, 2021, 29, 6193-6200.	2.2	1
62	Vaccination Schedules. Hematologic Malignancies, 2021, , 77-105.	0.2	1
63	Victorian Specialist Immunisation Services (VicSIS) – bolstering adult clinics for COVID-19 vaccines. Human Vaccines and Immunotherapeutics, 2022, 18, 1-6.	3.3	1
64	More than a feeling: new approach required for assessing immunosuppression. Leukemia and Lymphoma, 2014, 55, 975-976.	1.3	0
65	The long and short of antibiotic management for neutropenic fever in patients with haematological malignancy. Lancet Haematology,the, 2022, , .	4.6	0